Treatment of moderate-to-severe atopic eczema in adults within the UK: Results of a national survey of dermatologists by Taylor K et al.
This work is licensed under a Creative Commons Attribution 4.0 International License 
Newcastle University ePrints - eprint.ncl.ac.uk 
Taylor K, Swan DJ, Affleck A, Flohr C, Reynolds NJ.  
Treatment of moderate-to-severe atopic eczema in adults within the U.K: 
Results of a national survey of dermatologists.  
British Journal of Dermatology 2017 
DOI: https://doi.org/10.1111/bjd.15235 
Copyright: 
©2016 The Authors. British Journal of Dermatology. Published by John Wiley & Sons Ltd on behalf of 
British Association of Dermatologists. This is an open access article under the terms of the Creative 
Commons Attribution License, which permits use, distribution and reproduction in any medium, provided 
the original work is properly cited. 
DOI link to article: 
https://doi.org/10.1111/bjd.15235 
Date deposited: 
03/05/2017 
GENERAL DERMATOLOGY
BJD
British Journal of Dermatology
Treatment of moderate-to-severe atopic eczema in adults
within the U.K.: results of a national survey of
dermatologists
K. Taylor,1 D.J. Swan,2 A. Affleck,3 C. Flohr4 and N.J. Reynolds2,5 in collaboration with the U.K. Translational
Research Network in Dermatology and the U.K. Dermatology Clinical Trials Network
1Policy, Ethics and Life Sciences Research Centre and 2Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, U.K.
3Newcastle University Business School, Newcastle upon Tyne, U.K.
4Unit for Population-Based Dermatology Research, St John’s Institute of Dermatology, Guy’s and St Thomas’ Hospital NHS Foundation Trust and King’s College,
London, U.K.
5Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne, U.K.
Correspondence
Nick J. Reynolds.
E-mail: nick.reynolds@ncl.ac.uk
Accepted for publication
1 December 2016
Funding sources
There was no external funding specifically for this
project. N.J.R.’s laboratory and research are sup-
ported by the National Institute for Health
Research (NIHR) Newcastle Biomedical Research
Centre. C.F. holds an NIHR Career Development
Fellowship. The funding agencies played no role in
the study design, data collection, data analysis,
manuscript preparation or publication decisions.
Conflicts of interest
N.J.R. has grant support from a BBSRC Case stu-
dentship with Stiefel/GSK, and from Genentech
and Bristol Myers Squibb for atopic eczema-related
research and clinical trials, and has conducted con-
sultancy for Genentech through Newcastle Univer-
sity. N.J.R. is chair of U.K. TREND. C.F. has
conducted consultancy for Genentech and Sanofi.
K.T. and D.J.S. made equal contributions to this
work.
DOI 10.1111/bjd.15235
Summary
Background Little is known about U.K. dermatologists’ treatment approaches
towards adult patients with recalcitrant moderate-to-severe atopic eczema.
Objectives We wanted to learn about (i) treatment approaches used for this disease
in the U.K.; (ii) factors that influence treatment decisions and (iii) perceived gaps
in evidence on treatment safety and efficacy, and priorities for future trials.
Methods We conducted an online survey of consultant-level dermatologists in the
U.K.
Results Sixty-one respondents from over 30 centres reported on management of
moderate-to-severe atopic eczema in adults, outwith the context of an acute flare.
Phototherapy or psoralen–ultraviolet A was the most common therapeutic modal-
ity chosen first line (46%), and this was usually narrowband ultraviolet B. Sys-
temic therapy was chosen as a first-line approach by 36% of dermatologists.
Azathioprine was the commonest drug reported being used as first line followed
by oral corticosteroids, ciclosporin and methotrexate. Methotrexate was the most
common second-line treatment of respondents. The key factors that influenced
decision making on the use of phototherapy and systemic agents were the
respondent’s clinical experience, results of baseline tests (systemic agents) and
knowledge of both efficacy and acute and chronic side-effect profiles. The most
important evidence gaps identified were the relative effectiveness of treatments,
the alternatives to current approaches and the safety of long-term maintenance
treatment. With regard to future trials, respondents suggested that priority should
be given to studies involving methotrexate.
Conclusions While survey study designs have limitations, we found that photother-
apy, in particular narrowband ultraviolet B, was respondents’ preferred first-line
treatment for adults with recalcitrant moderate-to-severe atopic eczema, perhaps
reflecting access to, and clinical experience of, this approach. Azathioprine is
widely used as a longer-term maintenance treatment.
What’s already known about this topic?
• Clinical trials have shown that phototherapy is an effective treatment for moderate-
to-severe atopic eczema in adults, but the extent to which it is used in clinical
practice in the U.K. is unknown.
• Ciclosporin is currently the only licensed systemic treatment for moderate-to-severe
atopic eczema in adults.
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• It is known that other systemic drugs are widely prescribed off-label, but the only
reliable data on their use come from a systematic survey of dermatologists and pae-
diatricians published in 2013 on the treatment of paediatric eczema across Europe.
What does this study add?
• The majority of U.K. consultant-level dermatologists use phototherapy and systemic
drugs for treating adults with moderate-to-severe atopic eczema.
• Key factors influencing the treatment decisions made by U.K. dermatologists were
their own clinical experience, results of baseline tests, knowledge of treatment effi-
cacy and knowledge of the acute and chronic side-effect profiles of the various
treatment options.
• We report the clinical trials that dermatologists would like to see performed; a
study involving methotrexate was identified as a priority.
Atopic eczema is a disabling long-term condition. Although it
is often considered a disease of childhood, the prevalence of
atopic eczema in adults is about 3–10%.1,2 Atopic eczema is
characterized by skin barrier dysfunction and chronic inflam-
mation. The itching, associated loss of sleep and skin infec-
tions that accompany moderate-to-severe disease significantly
impair quality of life. Although around 60% of children will
go into remission by adolescence, refractory moderate-to-
severe atopic eczema in adults usually runs a prolonged and
protracted course,3 typically affecting over 40% of the body
surface area.4,5 While many adult patients respond to treat-
ment with topical corticosteroids or calcineurin inhibitors and
moisturizers, a significant percentage have recalcitrant disease.
Adults with moderate-to-severe atopic eczema refractory to
topical treatments may be considered for phototherapy or sys-
temic drug treatment. Currently, ciclosporin is the only oral
drug licensed for refractory atopic eczema. It should be used
only for a limited period (the British National Formulary rec-
ommends 2 months maximum) because prolonged use is
associated with hypertension, renal impairment and risk of
cancer.6–11
In 2000 a systematic review12 highlighted the lack of thera-
peutic options for patients with refractory atopic eczema and
underscored the need for robust testing of a range of treat-
ments for the disease. Investigators responded with clinical tri-
als assessing a variety of modalities of phototherapy and a
number of systemic agents, often adapted from use in other
autoimmune and inflammatory conditions. In 2012, the Euro-
pean Dermatology Forum, the European Academy of Derma-
tology and Venereology, the European Task Force on Atopic
Dermatitis, the European Federation of Allergy, the European
Society of Pediatric Dermatology and the Global Allergy and
Asthma European Network published a consensus set of guide-
lines for the treatment of atopic eczema.9 This summarized
the evidence base for phototherapy and systemic agents. The
2013 European TREatment of severe Atopic eczema in chil-
dren Taskforce (TREAT) survey provided valuable information
about treatment of atopic eczema in children across eight
European countries, including the U.K.2 Whether or not der-
matologists are following national and international guidelines
on treatment of atopic eczema in adults, and indeed their
degree of knowledge of the evidence base, is not known.
The aim of this study was to survey current treatment
approaches by consultant-level dermatologists for adults with
refractory moderate-to-severe eczema across U.K. dermatology
departments. Specifically we wanted to (i) learn about the
hierarchy of treatment decisions made by dermatologists and
the factors governing those decisions, (ii) determine the
extent of use of off-label systemic therapies and (iii) identify
perceived gaps in evidence and thereby inform the design of
future clinical studies.
Patients and methods
A web-based survey instrument was designed, based on the
question set used in the paediatric TREAT study,2 but adapted
for adult patients and including phototherapy (Appendix S1;
see Supporting Information). We used commercially available
survey software (SurveyMonkey) and the structure and indi-
vidual questions were validated using the cognitive theory
method of Willis.13 Each question was systematically assessed
for problems with comprehension, decision and response pro-
cesses, and retrieval from memory. Comprehensibility was
ensured by balancing the intent of each question and the
appropriateness of the use of language for the survey
audience.
Assessing respondent decision processes involved ensuring
clarity and avoiding formulations where respondents could
give ‘socially desirable’, rather than truthful, responses. Multi-
ple-choice options, including ‘Don’t know’, were matched to
the questions and chosen to yield the quantitative information
required while ensuring consistency across the survey instru-
ment. Time periods were chosen to reflect the compromise
between likely accurate recall and achieving useable data.
Free-text responses were sought to questions about future
studies so that respondents were not constrained to particular
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views held by the authors. A piloting exercise was undertaken
involving 11 dermatologists before finalizing the question set.
For the purpose of the survey, we defined moderate-to-
severe atopic eczema as atopic eczema ‘which is not ade-
quately controlled by standard and optimised topical treatment
(including emollients, topical steroids and topical calcineurin
inhibitors), apart from occasional short-term flares caused by
skin infection for example’ (Appendix S1), and all the results
reported relate to this definition.
A link to the survey instrument was distributed by e-mail
to the members of both the U.K. Translational Research
Network in Dermatology (U.K. TREND) and the U.K. Derma-
tology Clinical Trials Network (U.K. DCTN). In total, 334
e-mails were sent, reaching the target group of U.K. consul-
tant dermatologists and associate specialists. Some recipients
were members of both networks, so in order to reduce the
possibility that recipients would reply more than once, the
SurveyMonkey system was configured to permit only one sub-
mission per IP address. The questionnaire was open from 3 to
27 June 2013, and 77 responses were received. Of these, two
respondents were working outside of the U.K. and 14 were
nonconsultant grades. As we wished to focus on U.K. practice,
and responses from nonconsultant-level grades most likely
overlap with those of their supervisors, these data were
excluded, leaving 61 valid responses.
To reduce potential errors resulting from inaccurate recall
of patient numbers referred or treated over long time scales,
respondents were offered ranges, rather than being asked to
supply discrete figures. Throughout the paper we therefore
provide estimates of the numbers of patients referred or treated.
These were calculated using data provided to us by the British
Association of Dermatologists (BAD) (M. Benham, personal
communication), from which we conservatively estimated that
there were 729 practising consultant, or equivalent grade, der-
matologists in the U.K. in 2013. We used a standard statistical
approach to obtain median values of group data:
Med ¼ Bi þ ð
n
2 cfp
fm
Þi
where Bi is the lower class boundary of the group containing
the median, n is the total number of data points, cfp is the
cumulative frequency of the groups before the median group,
fm is the frequency of the median group and i is the group
interval.
Results
Respondents
The 61 valid respondents comprised consultant dermatologists
(74%), clinical academics (honorary consultant dermatolo-
gists; 15%) and associate specialists in dermatology (11%).
Based on the membership of the U.K. DCTN and U.K. TREND,
the overall response rate for this group was 183%. The
respondents came from over 30 centres from 31 different
cities across England, Wales and Scotland. The majority saw
their adult dermatology patients in university teaching hospi-
tals (56%), followed by general hospitals (41%), with the
remainder seeing their patients in private practice (2%) or the
community (2%).
Number of newly referred patients and treatment choices
We asked respondents to estimate the number of newly
referred adults with refractory moderate-to-severe atopic
eczema seen over an average 3-month period. These data are
shown in Table S1 (see Supporting Information). Using these
data and the formula above, we calculated the median number
of new referrals of adults with moderate-to-severe atopic
eczema per dermatologist over a 3-month period to be 86.
There was a trend for a slightly greater number of referrals
reported by consultants from teaching compared with district
hospitals, consistent with the location of dedicated atopic
eczema clinics in larger centres.
Therapy selection
All respondents reported that adult patients with refractory
moderate-to-severe atopic eczema would be treated using
either phototherapy/psoralen–ultraviolet A (PUVA) pho-
tochemotherapy or oral systemic treatment (such as oral corti-
costeroids, ciclosporin, azathioprine or methotrexate).
Phototherapy/PUVA was the most common therapeutic
modality chosen as the first-line option in the management of
moderate-to-severe atopic eczema in adults (46%) (Table S2;
see Supporting Information). Systemic therapy was chosen by
36% as the first-line approach, but was the most commonly
chosen second-line approach (49%). A small number (5%)
indicated they would never initiate or refer for phototherapy/
PUVA, but all respondents indicated they would prescribe a
systemic therapy as a first-, second- or third-line choice.
Admission into hospital and referral for day-case topical treat-
ment were predominantly reserved for third-line options.
The numbers of patients treated with the two most com-
mon therapeutic options are shown in Table S3 (se Supporting
Information). Using these data and the formula above, the
median numbers of patients treated per dermatologist over an
average 3-month period with phototherapy/PUVA and oral
systemic therapy were calculated as 27 and 48, respectively.
Phototherapy
Figure 1 shows that of the 58 respondents using photother-
apy/PUVA, the majority (93%) would choose narrowband
UVB as the first-line modality and PUVA as second line
(64%). Interestingly, 83% of respondents would never con-
sider broadband UVB and 93% would never consider UVA
(TL09) or UVA1.
Respondents’ own clinical experience (97% agreed or
strongly agreed) and their knowledge of acute (90%) and
© 2016 The Authors. British Journal of Dermatology
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chronic (95%) side-effect profiles were major factors influenc-
ing choice of phototherapy for treatment (Table 1).
Systemic treatments
As shown in Figure 2, azathioprine was the preferred first-line
systemic agent reported, ahead of oral corticosteroids, ciclos-
porin and methotrexate. Interestingly methotrexate was the
most commonly used second-line agent (Fig. 2). Although
mycophenolate mofetil was rarely used as the first-line agent,
it was the preferred third-line agent (Fig. 2). Very occasional
use of systemic tetracyclines, doxycycline, high-dose intra-
venous immunoglobulin, hydroxycarbamide, alitretinoin (if
hands are involved) and thioguanine was also reported. The
median numbers of patients started on systemic therapies per
dermatologist over a typical 3-month period were azathioprine
168, ciclosporin 153, methotrexate 136, mycophenolate
mofetil 059 and oral corticosteroids 106 (calculated from the
formula above and the data in Table S4; see Supporting Infor-
mation).
Marked differences in the average duration of treatment
between agents were reported (Fig. 3a). On average, azathio-
prine treatment was continued for 138 months, compared
with 58 months for ciclosporin. Methotrexate was continued
for 151 months on average, similarly to azathioprine. Nota-
bly, the majority of respondents reported using ciclosporin for
a maximum of 7–12 months, compared with > 24 months
for azathioprine and methotrexate (Fig. 3b).
Fig 1. Relative reported priority for
phototherapy selection by U.K. dermatologists
in the management of moderate-to-severe
atopic eczema in adults. UV, ultraviolet.
Table 1 Factors influencing consultant-level dermatologists’ choice of phototherapy/psoralen–ultraviolet A for moderate-to-severe atopic eczema
in adults
Strongly agree Agree Neutral Disagree Strongly disagree
Evidence base for treatment efficacy including support
by randomized controlled trials
15 (26) 17 (29) 19 (33) 7 (12) 0
National or international guidelines 10 (17) 25 (43) 23 (40) 0 0
Expert opinion disseminated through lectures
and clinical meetings
9 (16) 33 (57) 16 (28) 0 0
Own clinical experience 24 (41) 32 (55) 2 (3) 0 0
Acute side-effect profile 18 (31) 34 (59) 5 (9) 1 (2) 0
Potential long-term side-effect profile 21 (36) 34 (59) 3 (5) 0 0
Patient choice 17 (29) 35 (60) 4 (7) 2 (3) 0
All values are n (%).
Fig 2. Relative reported priority of systemic
therapies in the management of moderate-to-
severe atopic eczema in adults.
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The main factors influencing dermatologists’ choice of sys-
temic agent for patients with moderate-to-severe atopic
eczema are shown in Table 2. The most frequently reported
factors were results of baseline tests and comorbidities, and
respondents’ own clinical experience of systemic agents. Der-
matologists’ knowledge of treatment efficacy and potential
side-effect profiles also featured prominently.
When asked about factors influencing their choice of initial
dose of oral systemic agent, 95% of the respondents either
agreed or strongly agreed that thiopurine methyltransferase
status at baseline would influence their choice.
Unmet needs and future studies
Respondents were asked, ‘what is the most important cur-
rently unanswered question about the treatment of moderate-
to-severe atopic eczema in adults?’ Three common themes
emerged from the 47 free-text responses. These can be sum-
marized as, ‘which treatments are the most effective?’
(n = 24, 51%), ‘what alternatives are there to current
approaches?’ (n = 15, 32%) and ‘how safe is long-term main-
tenance treatment?’ (n = 10, 21%).
When questioned on the most important randomized con-
trolled trial (RCT) that should be performed on treatment of
moderate-to-severe atopic eczema in adults, the majority of
the 45 respondents (n = 31, 69%) identified comparative
studies between either two systemic treatments, or a systemic
treatment and phototherapy. Respondents were then asked to
describe, in their opinion, the most important RCT that
should be performed in relation to systemic therapy, and 27
of 37 (73%) identified a trial involving methotrexate as the
most important. Within this group, 18 respondents (49%)
proposed a trial in which methotrexate would be compared
with azathioprine, and six respondents (16%) proposed
methotrexate vs. ciclosporin.
When questioned on the most important RCT that should
be performed in relation to phototherapy, the greatest
response (18 of 39 respondents, 46%) was for active-com-
parative studies. Eight respondents (21%) proposed
Table 2 Factors influencing dermatologists’ choice of systemic therapy for moderate-to-severe atopic eczema in adults
Strongly
agree Agree Neutral Disagree
Strongly
disagree
Cost 5 (9) 6 (11) 24 (43) 12 (21) 9 (16)
Results of baseline tests and comorbidities 39 (70) 17 (30) 0 0 0
Medium-term (> 3 months) efficacy and potential
for maintenance treatment
29 (52) 26 (46) 1 (2) 0 0
Short-term (< 3 months) efficacy 23 (41) 31 (55) 1 (2) 1 (2) 0
Acute side-effect profile 26 (46) 27 (48) 2 (4) 0 1 (2)
Potential long-term side-effect profile 29 (52) 25 (45) 1 (2) 1 (2) 0
Evidence base for treatment efficacy including support
by randomized controlled trials
13 (23) 29 (52) 13 (23) 1 (2) 0
National or international guidelines 11 (20) 30 (54) 14 (25) 1 (2) 0
Expert opinion disseminated through lectures
and clinical meetings
12 (21) 36 (64) 7 (13) 1 (2) 0
Own clinical experience of systemic agents 31 (55) 25 (45) 0 0 0
Patient choice 25 (45) 26 (46) 4 (7) 1 (2) 0
All values are n (%).
(a)
(b)
Fig 3. (a) Average and (b) maximum duration of treatment reported
by U.K. dermatologists for specified therapeutic agents.
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comparisons of one phototherapy with another, and seven of
these (18% of the total) wished to compare TL01 UVA with
PUVA. Another 10 (26%) suggested a comparison of any form
of phototherapy with another treatment such as systemic
drugs or topical steroids. Issues around duration of remission
(n = 7, 18%) and dosimetry regimens (n = 4, 10%) were also
raised.
Discussion
Although atopic eczema is one of the most common der-
matoses affecting adults that is treated by dermatologists,14,15
the treatment modalities used, the hierarchy of their use in
practice, and the rationale guiding therapeutic decision mak-
ing are poorly understood. We found that U.K. dermatologists
use phototherapy and systemic drugs to treat adults with recal-
citrant moderate-to-severe atopic eczema, and that photother-
apy/PUVA was the most common first-line modality chosen.
In line with trial evidence and published guidelines, narrow-
band UVB was the most common form of phototherapy used.
Fewer dermatologists chose systemic therapy as a first-line
approach, but it was the most common modality used second
line. Azathioprine was the most frequently prescribed systemic
drug, even though ciclosporin is the only drug licensed for
this indication. Azathioprine is used for maintenance therapy
over longer periods than ciclosporin. Methotrexate, the most
frequently used second-line systemic, was also used for
longer-term maintenance therapy.
To the best of our knowledge, this is the first national sur-
vey to address the hierarchy of current treatment approaches
by consultant-level dermatologists for adults with refractory
moderate-to-severe eczema. We received responses from a
good cross-section of consultant-level dermatologists working
in a variety of clinical situations and in different geographical
locations across the U.K. One of the main shortcomings of
this study is the low survey response rate. Although this is
typical for online surveys,16,17 and the relationship between
response rate and nonresponse bias is not straightforward,18
this might have resulted in bias. As we selected our partici-
pants from the membership of the U.K. TREND and U.K.
DCTN groups, we also selected a sample with a strong interest
in research. This, combined with the low response rate,
potentially limits the statistical generalizability of our findings.
On the other hand, in areas of overlap with previously pub-
lished surveys, our data appear consistent and aligned.2,19,20
Our finding that > 90% of the responding U.K. dermatolo-
gists would choose narrowband UVB as their first-line pho-
totherapy modality is in line with evidence from RCTs4 and
recently published European guidelines.21 However, it is inter-
esting that respondents’ own clinical experience and knowl-
edge of acute and chronic side-effect profiles (rather than
their knowledge of the evidence base for treatment efficacy)
appeared to be the major factors influencing their choice.
Among paediatric dermatologists and paediatricians in Eur-
ope,2 ciclosporin was the most commonly used first- and sec-
ond-line medication. However, notably there was clear regional
variation, and within the U.K. azathioprine appeared to be the
most prescribed first-line systemic agent for children, although
ciclosporin was almost as commonly used.2 Use of azathioprine
as the first-line choice of systemic is in line with a growing
body of literature, including guidelines on the safe and effective
prescription of azathioprine for dermatological conditions pub-
lished by the BAD in 2011, and later studies.5,22–24 Systematic
reviews and European guidelines have also recommended
consideration of azathioprine for treatment of refractory mod-
erate-to-severe atopic eczema.9,25 On the other hand, although
treatment guidelines report a largely unfavourable risk-to-bene-
fit ratio for the use of systemic corticosteroids,9 a surprisingly
high percentage of respondents (42%) reported using systemic
corticosteroids as the first-line choice. This might reflect short-
term treatment, particularly if admission to hospital is not avail-
able, although participants were asked to consider their answers
outwith the treatment of acute flares, and we did not ask about
the duration of use of systemic steroids.
The reported average and maximum durations of therapy
for azathioprine and ciclosporin provide insight into the dif-
ferent treatment approaches offered by these drugs. The
reported maximum duration of use of ciclosporin is in line
with the National Institute of Health and Care Excellence
guidelines for psoriasis, which suggest a maximum of 1 year
due to the risk of hypertension, renal impairment and
cancer.6–8,11 The average length of azathioprine treatment was
considerably longer at 138 months, compared with
58 months for ciclosporin. Furthermore, the reported maxi-
mum treatment times with azathioprine indicate that the
majority of our respondents considered it as a longer-term
(> 2-year) treatment or maintenance option. Nevertheless, the
BAD guidelines caution about the prolonged use of azathio-
prine in part because of uncertainty over cancer risk.22 Reas-
suringly, 95% of respondents were aware that thiopurine
methyltransferase status should be checked prior to initiating
azathioprine therapy.22 The factors reported as influencing
respondents’ choice of systemic agent provide evidence that
consultant dermatologists are aware of the risks and benefits
involved with specific treatment modalities. Although the evi-
dence base to support the efficacy of methotrexate9,24,26 in
refractory moderate-to-severe atopic eczema is less robust than
for azathioprine and ciclosporin,9 it appears at least to be
equally as effective as azathioprine.24
The most important unanswered questions and research trial
priorities identified by our survey of consultant dermatologists
were consistent with a recent study specifically designed to
identify and prioritize important research questions among
patients, carers, clinicians and researchers for the treatment of
atopic eczema.19 Our findings also align with a recently pub-
lished eDelphi exercise performed by U.K. TREND that high-
lighted identification of novel systemic treatments for adult
eczema as one of the top 10 translational research questions in
inflammatory skin disease.20
We sought the views of our respondents on RCTs they
would like to see conducted. Comparative studies between
two systemic treatments or between a systemic treatment and
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phototherapy were identified as the most important RCTs that
should be performed, followed by single-agent placebo-con-
trolled studies. Methotrexate was the most commonly identi-
fied systemic for future trials. Another approach, particularly
suited to addressing questions of long-term safety and disease
control, is to study large national patient cohorts, with long-
term follow-up. Such a study is currently being set up under
the auspices of U.K. TREND and will provide important com-
parative data not only on conventional systemics and pho-
totherapy, but also on biological agents, once these have
entered routine clinical practice.
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